Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.

ABSTRACT:

Purpose

In some patients with Hodgkin lymphoma (HL), proton beam therapy (PBT) may reduce the risk of radiation-related cardiovascular disease (CVD) and second cancers (SC) compared with photon radiation therapy (RT). Our aim was to identify patients who benefit the most from PBT in terms of predicted 30-year absolute mortality risks (AMR₃₀) from CVD and SC, taking into account individual background, chemotherapy, radiation, and smoking-related risks.

Methods and materials

Eighty patients with supradiaphragmatic HL treated with PBT between 2015 and 2019 were replanned using optimal photon RT. To identify patients predicted to derive the greatest benefit from PBT compared with photon RT, doses and AMR₃₀ from CVD and SC of the lung, breast, and esophagus

SUBMITTER: Ntentas G 

PROVIDER: S-EPMC8865523 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature